Circulating serum miRNAs as potential biomarkers for nephroblastoma

Pediatric Blood and Cancer

Volumn 62, Issue 8, 2015, Pages 1360-1367

  Ludwig, Nicole ^a   Nourkami Tutdibi, Nasenien ^a   Backes, Christina ^b   Lenhof, Hans Peter ^b   Graf, Norbert ^a   Keller, Andreas ^b   Meese, Eckart ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Circulating miRNA; MiR 100 5p; MiR 130b 3p; MiR 143 3p; Serum; Wilms tumor

Indexed keywords

LET 7A 5P; LET 7F 5P; MICRORNA; MICRORNA 100 5P; MICRORNA 101 3P; MICRORNA 126 3P; MICRORNA 130B 3P; MICRORNA 143 3P; MICRORNA 17 5P; MICRORNA 181B 5P; MICRORNA 1825; MICRORNA 18A 5P; MICRORNA 195 5P; MICRORNA 223 3P; MICRORNA 24 3P; MICRORNA 320A; MICRORNA 335 5P; MICRORNA 3651; MICRORNA 572; MICRORNA 638; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN100 MICRORNA, HUMAN; MIRN130 MICRORNA, HUMAN; MIRN143 MICRORNA, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE; GENE OVEREXPRESSION; HEMOLYSIS; HUMAN; NEPHROBLASTOMA; PATIENT CODING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; BLOOD; CHILD; GENE EXPRESSION PROFILING; GENETICS; PRESCHOOL CHILD; WILMS TUMOR;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 84932197919     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25481     Document Type: Article

References (36)

1. Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009; 21:357-364.
2. Davidoff AM. Pediatric oncology. Semin Pediatr Surg 2010; 19:225-233.
3. Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms' tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am 2000; 27:443-454.
4. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 2002; 38:79-82.
5. Bartel DP. Micrornas: Genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
6. Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sultmann H, Muley T, Kuner R. Serum mir-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 2013; 80:223-227.
7. Keller A, Leidinger P, Gislefoss R, Haugen A, Langseth H, Staehler P, Lenhof HP, Meese E. Stable serum mirna profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 2011; 8:506-516.
8. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J. Serum microrna-155 as a potential biomarker to track disease in breast cancer. PLoS ONE 2012; 7:e47003.
9. Zhao A, Li G, Péoc'h M, Genin C, Gigante M. Serum mir-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013; 94:115-120.
10. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY. Serum microrna expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58:610-618.
11. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011; 77:1265.e9-16.
12. Hofsli E, Sjursen W, Prestvik WS, Johansen J, Rye M, Trano G, Wasmuth HH, Hatlevoll I, Thommesen L. Identification of serum microrna profiles in colon cancer. Br J Cancer 2013; 108:1712-1719.
13. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating micrornas as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105:10513-10518.
14. Kort EJ, Farber L, Tretiakova M, Petillo D, Furge KA, Yang XJ, Cornelius A, Teh BT. The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res 2008; 68:4034-4038.
15. Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, Boccon-Gibod L, Graf N, Pritchard-Jones K, O'Sullivan M. Mirna profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS ONE 2013; 8:e53417.
16. Wegert J, Ishaque N, Vardapour R, Geörg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, Keller A, Grimm C, Kneitz S, Williams RD, Chagtai T, Pritchard-Jones K, van Sluis P, Volckmann R, Koster J, Versteeg R, Acha T, O'Sullivan MJ, Bode PK, Niggli F, Tytgat GA, van Tinteren H, van den Heuvel-Eibrink MM, Meese E, Vokuhl C, Leuschner I, Graf N, Eils R, Pfister SM, Kool M, Gessler M. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 2015; 27:298-311.
17. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum P, Dahlsveen IK. Assessing sample and mirna profile quality in serum and plasma or other biofluids. Methods 2013; 59:S1-S6.
18. Torrezan GT, Ferreira EN, Nakahata AM, Barros BD, Castro MT, Correa BR, Krepischi AC, Olivieri EH, Cunha IW, Tabori U, Grundy PE, Costa CM, de Camargo B, Galante PA, Carraro DM. Recurrent somatic mutation in drosha induces microrna profile changes in Wilms tumour. Nat Commun 2014; 5:4039. doi: 10.1038/ncomms5039.
19. Wu MK, Sabbaghian N, Xu B, Addidou-Kalucki S, Bernard C, Zou D, Reeve AE, Eccles MR, Cole C, Choong CS, Charles A, Tan TY, Iglesias DM, Goodyer PR, Foulkes WD. Biallelic dicer1 mutations occur in Wilms tumours. J Pathol 2013; 230:154-164.
20. Anglesio MS, Wang Y, Yang W, Senz J, Wan A, Heravi-Moussavi A, Salamanca C, Maines-Bandiera S, Huntsman DG, Morin GB. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol 2013; 229:400-409.
21. Zhao C, Zhang J, Zhang S, Yu D, Chen Y, Liu Q, Shi M, Ni C, Zhu M. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. Oncol Rep 2013; 30:276-284.
22. Kotb S, Mosharafa A, Essawi M, Hassan H, Meshref A, Morsy A. Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumour Biol 2014; 35:12613-12617.
23. Zhang ZQ, Meng H, Wang N, Liang LN, Liu LN, Lu SM, Luan Y. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol 2014; 9:135. doi: 10.1186/1746-1596-9-135.
24. Senanayake U, Das S, Vesely P, Alzoughbi W, Frohlich LF, Chowdhury P, Leuschner I, Hoefler G, Guertl B. Mir-192, mir-194, mir-215, mir-200c and mir-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 2012; 33:1014-1021.
25. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, Zanesi N, Alder H, D'Elia G, Gramantieri L, Bolondi L, Lanza G, Querzoli P, Angioni A, Croce CM, Negrini M. Oncogenic role of mir-483-3p at the IGF2/483 locus. Cancer Res 2010; 70:3140-3149.
26. Murray MJ, Raby KL, Saini HK, Bailey S, Wool SV, Tunnacliffe JM, Enright AJ, Nicholson JC, Coleman N. Solid tumors of childhood display specific serum microrna profiles. Cancer Epidemiol Biomarkers Prev 2015; 24:350-360.
27. Schmitt J, Backes C, Nourkami-Tutdibi N, Leidinger P, Deutscher S, Beier M, Gessler M, Graf N, Lenhof HP, Keller A, Meese E. Treatment-independent mirna signature in blood of Wilms tumor patients. BMC Genomics 2012; 13:379. doi: 10.1186/1471-2164-13-379.
28. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, Poon RT, Gao C, Luk JM. Circulating mir-15b and mir-130b in serum as potential markers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ Open 2012; 2:e000825.
29. Chiu LY, Kishnani PS, Chuang TP, Tang CY, Liu CY, Bali D, Koeberl D, Austin S, Boyette K, Weinstein DA, Murphy E, Yao A, Chen YT, Li LH. Identification of differentially expressed micrornas in human hepatocellular adenoma associated with type I glycogen storage disease: A potential utility as biomarkers. J Gastroenterol 2014; 49:1274-1284.
30. Wu C, Wang C, Guan X, Liu Y, Li D, Zhou X, Zhang Y, Chen X, Wang J, Zen K, Zhang CY, Zhang C. Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS ONE 2014; 9:e92292.
31. Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, Dai J, Hu Z, Zhou X, Chen L, Zhang Y, Li Y, Qiu H, Xing J, Liang Z, Ren B, Yang C, Zen K, Zhang CY. Expression profile of micrornas in serum: A fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010; 56:1871-1879.
32. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R. Deregulation of mir-100, mir-99a and mir-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012; 12:369. doi: 10.1186/1471-2407-12-369.
33. Szabo DR, Luconi M, Szabo PM, Toth M, Szucs N, Horanyi J, Nagy Z, Mannelli M, Patocs A, Racz Kigaz P. Analysis of circulating micrornas in adrenocortical tumors. Lab Invest 2014; 94:331-339.
34. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, Pass HI. MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 2013; 8:1156-1162.
35. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE 2011; 6:e24145.
36. MacLellan SA, MacAulay C, Lam S, Garnis C. Pre-profiling factors influencing serum microrna levels. BMC Clin Pathol 2014; 14:27. doi: 10.1186/1472-6890-14-27.